SCHEMBL4007243

SCHEMBL4007243

c1nc(NCCN2CCOCC2)c2cc(-c3ccc4ncnc(Nc5ccc(N6CCOCC6)cc5)c4c3)ccc2n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 13/20 0.67
CYP3A4 P08684 13/20 0.67
CLK4 Q9HAZ1 12/20 0.67
CYP2D6 P10635 10/20 0.67
USP2 O75604 9/20 0.67
ALDH1A1 P00352 8/20 0.67
HSD17B10 Q99714 6/20 0.67
CYP2C19 P33261 3/20 0.66
MAPT P10636 2/20 0.66
KDM4E B2RXH2 1/20 0.66
HPGD P15428 1/20 0.66
MAPK1 P28482 3/20 0.66
AHR P35869 1/20 0.66
HTT P42858 1/20 0.66
PI4KB Q9UBF8 1/20 0.65
TSHR P16473 2/20 0.62
LMNA P02545 1/20 0.60
HIF1A Q16665 1/20 0.60
EGFR P00533 2/20 0.57
PIK3CD O00329 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4007548 0.96 MAPK1 (0.63) CYP1A2CYP3A4CLK4CYP2D6USP2
SCHEMBL4010987 0.95 ALDH1A1 (0.64) CYP1A2CYP3A4CLK4CYP2D6USP2
SCHEMBL4013832 0.92 MAPK1 (0.60) CYP1A2CYP3A4CLK4CYP2D6USP2
SCHEMBL4008515 0.89 MAPT (0.80) CYP1A2CYP3A4CLK4CYP2D6USP2
SCHEMBL5103599 0.87 MAPT (0.62) CYP1A2CYP3A4CLK4CYP2D6USP2
SCHEMBL4791053 0.87 MAPT (0.61) CYP1A2CYP3A4CLK4CYP2D6USP2
SCHEMBL4759642 0.86 SRC (0.60) CYP1A2CYP3A4CLK4CYP2D6USP2
SCHEMBL4007152 0.84 MAPK1 (0.72) CYP1A2CYP3A4CLK4CYP2D6USP2
SCHEMBL14026142 0.84 MAPK1 (0.72) CYP1A2CYP3A4CLK4CYP2D6USP2
SCHEMBL4011562 0.84 PI4KB (0.62) CYP1A2CYP3A4CLK4CYP2D6USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1844004-B1 QUINAZOLINE DERIVATES AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LTD (GB) 2009-06-24 EP disclosed
US-20080114008-A1 Quinazoline Derivatives as Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114008-A1 Quinazoline Derivatives as Antiviral Agents IFNAR1, C5, EIF2AK2 CYP1A2 313/4885CYP3A4 122/4885CLK4 1443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.